Can the UK’s stock market produce another £200bn company? August 14, 2024 Seismic events or a shift in valuations are likely necessary for more UK stocks to be worth £200bn, analysts have told Morning Wire, after Astrazeneca became the first company in six years to pass the milestone.
Astrazeneca shares fall after FTSE giant’s forecast lift fails to inspire July 25, 2024 In the first half of 2024, Astrazeneca reported an 18 per cent year-on-year increase in total revenue, reaching $2.6bn (£2bn).
FTSE 100 companies BT, Vodafone and Astrazeneca to report earnings this week July 21, 2024 Key quarterly earning updates from FTSE 100 companies next week, include Vodafone, BT and Astrazeneca.
UK less ready for next pandemic than before Covid – Oxford vaccinologist July 3, 2024 The UK's state apparatus is less prepared to deal with a pandemic today than it was before Covid, one of the professors in charge of the Oxford Astrazeneca vaccine rollout has warned.
‘Nobel prize of engineering’ finalist Sunamp to raise Series B as it mulls public offering July 2, 2024 An innovative battery firm nominated for the "nobel prize of engineering" is set to raise a Series B funding round in a few months with a future IPO becoming an increasingly "realistic proposition", its boss has said.
Google Deepmind among nominees for ‘Nobel Prize of engineering’ June 28, 2024 AI-powered weather forecasting, innovative heat batteries and the rapid manufacturing scale-up of a Covid vaccine are the three cutting edge technologies nominated for an engineering award dubbed "the Nobel Prize of Engineering".
Oxford Biomedica issues new shares to secure a £17m investment June 18, 2024 Cell and gene therapy company Oxford Biomedica has announced a near £17m investment which will see it issue new shares to the London Stock Exchange.
Astrazeneca swallows up Canada-based Fusion Pharmaceuticals in £1.5bn move June 5, 2024 Astrazeneca has completed its $2bn (£1.5bn) acquisition of Canada-based Fusion Pharmaceuticals, in a deal first announced in March.
‘New era of growth’: FTSE 100 giant Astrazeneca aims to double revenue May 21, 2024 London-listed Astrazeneca reported revenue of $45.8bn in 2023 and growth of 19 per cent to $12.7bn in the first quarter of 2024.
Astrazeneca to build huge new cancer drug plant in Singapore May 20, 2024 Astrazeneca has said it will invest $1.5bn (£1.2bn) to build a manufacturing facility in Singapore to produce antibody drug conjugates (ADCs), a next-generation cancer treatment.